



\$200 Million
Follow-On Offering

svb Securities
 Joint Bookrunner
 February 2022

SVB Securities Serves as Joint Bookrunner for Traverse Therapeutics* (Nasdaq: TVTX) \$200 Million Follow-On Offering

Key Transaction Highlights

- Publicly launched February 27th, post-close after limited confidential marketing and priced February 28th post-close.
- The offering followed Traverse's February 17th announcement of the FDA's accelerated approval of FLS001 (see insert) to reduce pain/inflammation in adults with primary IgA Nephropathy (IgAN) at risk of rapid disease progression.
- Well oversubscribed from new and existing investors.
- Transaction consisted of 8,275,000 shares of common stock at a price of \$21.00 per share, representing a 3.4% discount to launch and a 5.8% discount to last sale, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,250,000 shares of common stock at a price of \$20.0000 per pre-funded warrant.
- Traverse intends to use the net proceeds from this offering to support the ongoing commercial launch of FLS001 (see insert) for IgAN and, if approved, the commercial launch of apertinib for FSGS, as well as for general corporate purposes, which may include clinical trial, manufacturing and other research and development expenses, capital expenditures, working capital and general and administrative expenses.
- This is SVB Securities' 4th leadman offering for Traverse and 8th book-run equity offering in 2022. SVB Securities previously served as a bookrunner in Traverse's March 2022 convertible senior notes offering as well as the Company's February 2021 and March 2015 follow-on offerings.

*You may wish to consult with the distributor, www.svb.com, if you wish to be a distributor from an SVB Securities distribution www.svb.com.

THESE SECURITIES ARE OFFERED THROUGH AN EXCLUSIVE FINANCIAL INSTITUTION OR FINANCIAL INSTITUTIONS AS AGENTS OF SVB SECURITIES LLC, THE BROKER-DEALER AND LEAD MANAGER OF THIS OFFERING. ONLY THE OFFEROR OR FINANCIAL INSTITUTION OR FINANCIAL INSTITUTIONS CAN PROVIDE THE TERMS AND CONDITIONS OF THIS OFFERING. THE OFFEROR, EXCLUSIVE FINANCIAL INSTITUTION, AND ITS AGENTS MAKE NO REPRESENTATION TO ANY OTHER FINANCIAL INSTITUTION.

8001108
 500 Park Street
 10th Floor
 Boston, MA 02116

CHARLOTTE
 200 Southern Street
 Suite 1000
 Charlotte, NC 28202

HOUSTON, TX
 4000 Westchase Boulevard
 Suite 300
 Houston, TX 77056

NEW YORK
 100 Avenue of the Americas
 10th Floor
 New York, NY 10013

SEATTLE, WA
 300 Columbia Street
 10th Floor
 Seattle, WA 98101

An SVB Company
www.svb.com